ClinicalTrials.gg
TerminatedNCT01846663Updated Jan 9, 2024Results posted

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

A Phase 4 interventional study of Placebo and Rifaximin in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Terminated at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study was determined to be infeasible.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.

Enrollment
16th of 18
6 · median 94
Started
2013
with 3 others
Phase 4
8 of 18
2 open now
Registered
10th of 18
by date
Lead sponsor
4 of 18
Bausch Health Americas, Inc.

Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 16th largest by enrollment, is one of 4 that started in 2013, is one of 8 in phase 4, and was the 10th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Hepatic Encephalopathy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

03

Conditions studied

  • Hepatic Encephalopathy

Keywords

  • Hepatic Encephalopathy
  • Liver Failure
  • Hepatic Insufficiency
  • Liver Diseases
  • Brain Diseases
  • Rifaximin
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-breast feeding female ≥ 18 years old
  • In remission from demonstrated overt HE
  • Had ≥1 episode of overt HE associated with liver disease within the last 6 months
  • MELD score of ≥ 19
  • Has a close family member or other personal contact who is familiar with the subject's HE, can provide continuing oversight to the subject and is willing to be available to the subject during the conduct of the trial

Exclusion criteria

Exclusion Criteria:

  • History of tuberculosis infection
  • Chronic respiratory insufficiency
  • Current infection and receiving antibiotics
  • Renal insufficiency requiring dialysis
  • Active spontaneous bacterial peritonitis infection
  • Intestinal obstruction or has inflammatory bowel disease
  • Active within the last 5 years
  • Current GI bleeding or has had a GI hemorrhage within past 3 months
  • Anemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Rifaximin

    Rifaximin, oral, 550 mg BID, 6 months of treatment

    Drug: Rifaximin

  • Placebo comparator
    Placebo

    Placebo, oral, 0 mg BID, 6 months of treatment

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo, oral, 0 mg BID, 6 months of treatment

  • Rifaximin, oral, 550 mg BID, 6 months treatment

    Also known as: XIFAXAN® Tablets

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode

    Time frame: 6 Months

Secondary outcomes

  1. Proportion of Participants With HE-related Hospitalization

    Time frame: 6 Months

07

Results

Posted Jan 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneRifaximinPlacebo
Started33
Completed01
Not completed32
Withdrew: Hepatic encephalopathy breakthrough10
Withdrew: Withdrawal by subject10
Withdrew: Adverse event12

Outcome measures

PrimaryProportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode
Time frame:
6 Months
Reported as:
Count of participants · Participants
Proportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode
ParticipantsRifaximinPlacebo
Proportion of Participants With Hepatic Encephalopathy (HE) Breakthrough Episode11
SecondaryProportion of Participants With HE-related Hospitalization
Time frame:
6 Months
Reported as:
Count of participants · Participants
Proportion of Participants With HE-related Hospitalization
ParticipantsRifaximinPlacebo
Proportion of Participants With HE-related Hospitalization11

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin2/3 (66.7%)3/3 (100%)2/3 (66.7%)
Placebo1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventRifaximinPlacebo
Hepatic cirrhosisHepatobiliary disorders2/30/3
EpistaxisRespiratory, thoracic and mediastinal disorders1/30/3
Respiratory failureRespiratory, thoracic and mediastinal disorders1/30/3
Renal failure acuteRenal and urinary disorders1/30/3
Septic shockInfections and infestations1/30/3
SepsisInfections and infestations1/30/3
AscitesGastrointestinal disorders1/31/3
BronchitisInfections and infestations1/30/3
Hepatic encephalopathyNervous system disorders1/31/3
Hepatorenal syndromeHepatobiliary disorders1/30/3
Most frequent other events
Showing 10 of 21
Most frequent other events
EventRifaximinPlacebo
Abdominal painGastrointestinal disorders1/30/3
Ammonia increasedInvestigations1/30/3
AnemiaBlood and lymphatic system disorders1/30/3
AnosmiaNervous system disorders0/31/3
Disturbance in attentionNervous system disorders0/31/3
DysesthesiaNervous system disorders0/31/3
DysgeusiaNervous system disorders0/31/3
DyslipidemiaMetabolism and nutrition disorders1/30/3
Escherichia infectionInfections and infestations0/31/3
FatigueGeneral disorders1/30/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)RifaximinPlaceboTotal
<=18 years000
Between 18 and 65 years325
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)RifaximinPlaceboTotal
Female123
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RifaximinPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American303
White033
More than one race000
Unknown or Not Reported000
08

Study locations

28 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294-0111, United States
  • Banner Research
    Phoenix, Arizona 85016, United States
  • University Of Arizona Liver Research Institute
    Tucson, Arizona 85724, United States
  • Southern California Liver Centers
    Coronado, California 92118, United States
  • UCSD Clinical & Translational Research Institute
    La Jolla, California 92037, United States
  • Loma Linda University Medical Center Transplantation Institute
    Loma Linda, California 92324, United States
  • University of Southern Califorina Keck School Of Medicine
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Salix Site
    New Haven, Connecticut 06520, United States
  • Salix Site
    Tampa, Florida 33606, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Northwestern University-Comprehensive Transplant Center
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Tulane Abdominal Transplant Research Office
    New Orleans, Louisiana 70112, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Salix Site
    Portland, Oregon 97239, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1610, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Brook Army Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Salix Site
    Galveston, Texas 77555, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • VCU/MCV Health Systems
    Richmond, Virginia 23298, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Feb 2016, 34 months.

Results were first posted in Jan 2024, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2013
First posted
May 3, 2013
StartActual
Apr 3, 2013
Primary completionActual
Feb 22, 2016
CompletionActual
Feb 22, 2016
Results first posted
Jan 9, 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01846663
Responsible party
Sponsor
First posted
May 3, 2013
Start date
Apr 3, 2013
Primary completion
Feb 22, 2016
Completion
Feb 22, 2016
Results posted
Jan 9, 2024
Last update
Jan 9, 2024

Study contacts

Varsha Bhatt, Ph.D.
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion